Exciting news! 🎉 Qwark’s AI pharmacy assistant (in beta) is now live and ready to answer any medication-related questions you may have!Try it out now!
  1. Drugs
  2. Xgeva
Xgeva Image

Xgeva

Free shipping
No membership fee
Qwark price promise
Qwark is committed to lowering your prescription prices. We will always recommend the best price we can find. If you find a lower price on an identical, in-stock product, tell us and we'll match it.

For more strengths and prices, please contact Qwark support

Need help?

Our patient support team is available Monday through Friday 8AM - 6PM PST, and Saturday 9AM - 12PM PST.

What Is Xgeva?

Xgeva is a brand-name medication that is prescribed to patients with cancer to address certain complications related to bone health. The active ingredient in Xgeva is denosumab, which belongs to a class of drugs called RANK ligand inhibitors. Patients with cancer are often susceptible to bone-related issues, such as bone loss and high blood calcium levels (hypercalcemia). Xgeva works by inhibiting the RANK ligand, a protein that plays a role in the breakdown of bone tissue. By blocking this protein, Xgeva helps prevent bone loss and reduces the risk of skeletal-related events, such as fractures, spinal cord compression, and the need for radiation or surgery to the bone. By addressing these bone-related complications, Xgeva aims to improve the quality of life for patients with cancer and reduce the risk of skeletal complications that can lead to pain and decreased mobility. It is typically administered as an injection by a healthcare professional, usually once every 4 weeks. As with any medication, Xgeva can have side effects, including low blood calcium levels, bone pain, fatigue, infections, and skin reactions. It is important to discuss the potential benefits and risks of Xgeva treatment with your healthcare provider to determine if it is the right option for you.

How to use Xgeva?

Xgeva, also known by its generic name denosumab, is a medication used to treat bone-related complications in patients with cancer. It is primarily prescribed to prevent bone fractures, treat bone loss (osteoporosis), and reduce high levels of calcium in the blood (hypercalcemia) that can occur as a result of cancer. Xgeva is administered as an injection under the skin (subcutaneous injection) once every 4 weeks or as directed by a healthcare professional. The injection is typically given in the upper arm, upper thigh, or abdomen. It is important to follow the dosage schedule provided by the doctor and not administer it more frequently or in larger amounts than prescribed. It is common to receive Xgeva injections in a healthcare setting such as a doctor's office or hospital. The injection should only be performed by a healthcare professional or under their supervision. The drug is usually given alongside other cancer treatments and may be part of a comprehensive strategy to manage bone-related complications in cancer patients. As with any medication, it is crucial to inform your doctor about any existing medical conditions or medications you are taking, as these may affect the efficacy or safety of Xgeva. Regular monitoring and follow-ups with your healthcare provider are necessary to assess the response to treatment and address any concerns or side effects that may arise. It is important to note that Xgeva can have side effects, including low calcium levels (hypocalcemia), infections, jaw problems (osteonecrosis of the jaw), and atypical fractures of the thigh bone. It is essential to report any new or worsening symptoms to your healthcare provider promptly. Please consult with your healthcare professional or pharmacist for specific instructions on how to use Xgeva and any precautions or warnings associated with its use.

There are several warnings associated with the use of Xgeva (denosumab), a medication prescribed for the treatment of bone loss and high blood calcium levels in cancer patients. It's important for patients and healthcare providers to be aware of these warnings to ensure safe and effective use of the drug. First, Xgeva can increase the risk of an uncommon but serious condition called osteonecrosis of the jaw (ONJ). This is a condition where the jawbone becomes exposed and does not heal properly. Symptoms may include jaw pain, swelling, numbness, loose teeth, and gum infection. Good oral hygiene and routine dental care are important to reduce the risk of developing ONJ. Second, Xgeva can also increase the risk of a similar condition called atypical femoral fractures. These are rare fractures of the thigh bone that can occur without significant trauma. Patients should be cautious of any new thigh or groin pain as it may be an early indication of a potential fracture. Furthermore, Xgeva can impair the healing process, so caution should be taken when considering elective dental procedures or other surgeries while on the medication. Lastly, Xgeva may affect the immune system, leading to an increased risk of infections. Patients should promptly report any signs of infection, such as fever, cough, or urinary tract symptoms, to their healthcare provider. It's important to note that these are not all the warnings associated with Xgeva. Patients should always consult with their healthcare provider and carefully review the medication guide to understand all the potential risks and benefits before starting this treatment.

Before taking Xgeva (denosumab), there are several important warnings and precautions that should be considered. It's important to note that this medication is a prescription drug that is used to treat bone loss and high blood calcium levels in patients with cancer. Some of the warnings and precautions include: 1. Hypocalcemia: Xgeva can lower the levels of calcium in the blood, leading to a condition called hypocalcemia. Your doctor may need to check your blood calcium levels and prescribe calcium and vitamin D supplements. 2. Osteonecrosis of the jaw (ONJ): ONJ is a serious condition that can occur as a rare but severe side effect of Xgeva. It causes the jaw bone to become exposed and can result in pain, swelling, or infection. Good oral hygiene and regular dental check-ups are recommended before starting treatment with Xgeva. 3. Atypical fractures: There have been rare reports of atypical fractures of the thigh bone in patients receiving Xgeva. Inform your doctor immediately if you experience any unusual pain, weakness, or discomfort in your thigh, hip, or groin area. 4. Hypersensitivity reactions: Some individuals may develop allergic reactions to Xgeva. Seek medical attention if you experience symptoms such as rash, itching, difficulty breathing, or swelling of the face, lips, tongue, or throat. 5. Pregnancy and breastfeeding: Xgeva can harm a developing fetus and it is not recommended for use during pregnancy. It is also unknown whether Xgeva passes into breast milk, so breastfeeding should be avoided while taking this medication. As always, it is important to discuss any concerns or questions with your healthcare provider before starting or stopping any medication. They will be able to provide you with personalized information regarding the risks and benefits of Xgeva in your specific situation.

Common side effects of Xgeva include fatigue, muscle or bone pain, joint pain, nausea, vomiting, diarrhea, constipation, loss of appetite, weight loss, headache, and low calcium levels (hypocalcemia). Rare but more serious side effects may include osteonecrosis (bone death) of the jaw, atypical fractures, and severe allergic reactions. Symptoms of jaw problems include jaw pain, swelling, or numbness. Atypical fractures, which can occur in the thigh bone, may cause sudden pain, swelling, or difficulty walking. Severe allergic reactions can manifest as rash, itching, swelling, severe dizziness, or difficulty breathing. It's important to consult your healthcare provider if you experience any of these side effects while taking Xgeva. They will be able to provide proper guidance and determine if any adjustments to your treatment are necessary.

The active ingredient in Xgeva is denosumab. It is a monoclonal antibody that specifically targets a protein called RANK ligand (RANKL). RANKL is involved in the activation of osteoclasts, which are cells responsible for breaking down bone tissue. By inhibiting RANKL, denosumab helps reduce bone loss and the risk of fractures in patients with cancer that has spread to the bones. It also helps lower high blood calcium levels by limiting the release of calcium from bones. Apart from denosumab, Xgeva also contains other inactive ingredients or excipients that help with the formulation and stability of the drug. These excipients can vary depending on the specific formulation and manufacturer of the medication. It is important to note that Xgeva is only available as a brand-name prescription drug and should be used under the guidance and supervision of a healthcare professional.

Xgeva is a brand-name prescription drug commonly used to treat bone loss and high blood calcium levels (hypercalcemia) in patients with cancer. When it comes to storing Xgeva, it is important to follow the instructions provided by your healthcare provider or outlined in the medication guide. Generally, Xgeva should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C). It should be kept in its original packaging, which helps to protect it from light and moisture. It is advisable to avoid freezing Xgeva as it may affect its effectiveness. As with any medication, it is essential to keep Xgeva out of reach of children and pets. Proper storage ensures that the medication maintains its stability and effectiveness throughout its shelf life. If you have any specific concerns or questions about storing Xgeva, it is best to consult with your healthcare provider or pharmacist for personalized advice.